New England Research & Management Inc. lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 7.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,748 shares of the company's stock after acquiring an additional 2,097 shares during the period. Johnson & Johnson makes up approximately 2.5% of New England Research & Management Inc.'s holdings, making the stock its 5th biggest holding. New England Research & Management Inc.'s holdings in Johnson & Johnson were worth $4,933,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the company. Tallon Kerry Patrick acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $290,000. Capital & Planning LLC raised its holdings in shares of Johnson & Johnson by 13.6% during the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock worth $221,000 after acquiring an additional 183 shares during the period. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new position in Johnson & Johnson in the 4th quarter worth $85,886,000. Finally, Global Wealth Management Investment Advisory Inc. increased its holdings in Johnson & Johnson by 6.8% during the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 33,957 shares of the company's stock worth $4,911,000 after purchasing an additional 2,171 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on JNJ shares. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Morgan Stanley lifted their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. Barclays reduced their price target on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Finally, The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $170.88.
Check Out Our Latest Report on Johnson & Johnson
Johnson & Johnson Trading Down 1.8%
NYSE JNJ traded down $2.84 on Tuesday, hitting $152.38. The company's stock had a trading volume of 6,406,138 shares, compared to its average volume of 7,958,458. The company's 50-day moving average is $154.03 and its 200 day moving average is $153.69. The firm has a market cap of $366.65 billion, a PE ratio of 16.95, a PEG ratio of 2.35 and a beta of 0.42. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is currently 57.84%.
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
